Regulatory And Commercial Insights To Maximize The Development Of Digital Health Solutions

Digital therapeutics and medicines (DTx) are becoming more widely recognized as potential treatments for conditions with significant unmet medical needs. At the same time, the regulatory environment for these digital health products is also becoming more complex and is rapidly evolving. As a result, developers of digital medicines are under significant pressure to meet the rising expectations for these innovative solutions—and to bring them to market faster and generate substantial revenue.

To better navigate where this sector in the industry is headed and track the evolution of these products, the FDA is looking to partner with DTx manufacturers. Keeping up-to-date with these initiatives and testing go-to-market models will help developers strategically plan and handle changing conditions and competition.

In this webinar, Robb Lawrence, Senior Vice President, Commercial Strategy, will provide several key insights into opportunities to leverage the regulatory pathways and highlight factors that will ultimately determine the commercial success or failure of digital products currently in development.